

08-07-00

A

JC901 U.S. PTO
08/04/00Please type a plus sign (+) inside this box → ☐Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | |
|---|--|---|
| UTILITY PATENT APPLICATION TRANSMITTAL (Only for new nonprovisional applications under 37 C.F.R. § 1.53(b)) | Attorney Docket No. | |
| | First Inventor or Application Identifier | RAJIT BANERJEE |
| | Title | METHODS FOR SIMULTANEOUS ISOLATION OF BIOLOGICALLY ACTIVE TRANSCRIPTION FACTORS AND DNA |
| | Express Mail Label No. | |

| | |
|--|--|
| APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents. | ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231 |
| 1. <input checked="" type="checkbox"/> * Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing) | 5. <input type="checkbox"/> Microfiche Computer Program (Appendix) |
| 2. <input checked="" type="checkbox"/> Specification [Total Pages 35] (preferred arrangement set forth below) <ul style="list-style-type: none">- Descriptive title of the Invention- Cross References to Related Applications- Statement Regarding Fed sponsored R & D- Reference to Microfiche Appendix- Background of the Invention- Brief Summary of the Invention- Brief Description of the Drawings (if filed)- Detailed Description- Claim(s)- Abstract of the Disclosure | 6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) <ul style="list-style-type: none">a. <input type="checkbox"/> Computer Readable Copyb. <input type="checkbox"/> Paper Copy (identical to computer copy)c. <input type="checkbox"/> Statement verifying identity of above copies |
| 3. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets 14] | ACCOMPANYING APPLICATION PARTS |
| 4. Oath or Declaration [Total Pages 2] <ul style="list-style-type: none">a. <input checked="" type="checkbox"/> Newly executed (original or copy)b. <input type="checkbox"/> Copy from a prior application (37 C.F.R. § 1.63(d)) (for continuation/divisional with Box 16 completed)<ul style="list-style-type: none">i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b). | 7. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) |
| | 8. <input type="checkbox"/> 37 C.F.R. § 3.73(b) Statement of Power of Attorney (when there is an assignee) |
| | 9. <input type="checkbox"/> English Translation Document (if applicable) |
| | 10. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 [Copies of IDS Citations] |
| | 11. <input type="checkbox"/> Preliminary Amendment |
| | 12. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized) |
| | 13. <input checked="" type="checkbox"/> * Small Entity Statement(s) filed in prior application, (PTO/SB/09-12) Status still proper and desired |
| | 14. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed) |
| | 15. <input type="checkbox"/> Other: _____ |

* NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: _____

Prior application information: Examiner _____ Group / Art Unit: _____

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

| | | | | |
|---|---------------------|---|--------------|--------------|
| 17. CORRESPONDENCE ADDRESS | | | | |
| <input type="checkbox"/> Customer Number or Bar Code Label | | (Insert Customer No. or Attach bar code label here) | | |
| or <input checked="" type="checkbox"/> Correspondence address below | | | | |
| Name | ARTHUR I DEGENHOLTZ | | | |
| Address | 32 VANDELINDA AVE. | | | |
| City | TEANECK | State | NJ | Zip Code |
| Country | US | Telephone | 201 692 1292 | Fax |
| | | | | 201 692 9764 |

| | | | |
|-------------------|----------------------------|-----------------------------------|----------|
| Name (Print/Type) | ARTHUR I DEGENHOLTZ | Registration No. (Attorney/Agent) | 22914 |
| Signature | <i>Arthur I Degenholtz</i> | Date | 8/3/2000 |

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**STATEMENT CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) & 1.27(b))--INDEPENDENT INVENTOR**

Docket Number (Optional)

Applicant, Patentee, or Identifier: RANJIT BANERJEE

Application or Patent No.: _____

Filed or Issued: _____

Title: METHODS FOR SIMULTANEOUS ISOLATION OF BIOLOGICALLY
ACTIVE TRANSCRIPTION FACTORS AND DNA

As a below named inventor, I hereby state that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees to the Patent and Trademark Office described in:

☒ the specification filed herewith with title as listed above.

☐ the application identified above.

☐ the patent identified above.

I have not assigned, granted, conveyed, or licensed, and am under no obligation under contract or law to assign, grant, convey, or license, any rights in the invention to any person who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern, or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

☒ No such person, concern, or organization exists.

☐ Each such person, concern, or organization is listed below.

Separate statements are required from each named person, concern, or organization having rights to the invention stating their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

RANJIT BANERJEE

NAME OF INVENTOR

NAME OF INVENTOR

NAME OF INVENTOR

Ranjit Banerjee
Signature of inventor

Signature of inventor

Signature of inventor

8/1/2000
Date

Date


Date

MAILING CERTIFICATE

I hereby certify that this correspondence
is being deposited with the United States Postal Service as
Express Mail, Certificate Number:

EK 502 521 586 US

in an envelope addressed to: Commissioner of Patents and
Trademarks, Washington, DC 20231 on the date indicated
below:


Arthur I. Degenholtz

Agent for Applicant

8/4/2000

Date



001080-2092960

**METHODS FOR SIMULTANEOUS ISOLATION OF BIOLOGICALLY ACTIVE
TRANSCRIPTION FACTORS AND DNA**

by

RANJIT BANERJEE

CROSS REFERENCE TO RELATED APPLICATIONS

This application is based on a Provisional Patent Application of Ranjit Banerjee, Serial Number 60/147,270 filed on August 5, 1999, titled "Methods for simultaneous isolation of biologically active transcription factors and DNA".

STATEMENT OF FEDERALLY SPONSORED RESEARCH

Work leading to the present invention was supported by National Institutes of Health (NIH) grants CA56302 and DA429259 awarded to Ranjit Banerjee.

FIELD OF THE INVENTION

The present invention relates primarily to the field of DNA isolation and nuclear and cytoplasmic cell extracts and more particularly to a rapid and efficient method for simultaneous isolation of biologically active transcription factors and DNA.

BACKGROUND OF THE INVENTION

In order to effectively characterize the gene modulation and transcriptional regulation in eukaryotic cells as well as in various diseases it is necessary to isolate the DNAs and the specific proteins, known as transcription factors (Mitchell and Tjian, 1989; Crabtree and Clipstone, 1994; and Rao et al., 1997), either from tissue samples obtained from different disorders or the cells collected from them grown in culture. The DNAs and proteins isolated from various sources must be intact and undegraded in order to be analyzed by various molecular techniques to evaluate their roles in pathogenic processes. It is often necessary to isolate various DNAs and proteins from a large number of samples over a short time period to determine when a specific gene activation occurs via modulation of a transcription factor, and to utilize them as land marks for identification of different disorders. However, such procedures are generally difficult and cumbersome. Most importantly these proteins should bind to specific DNA sequence motifs (Singh et al., 1985; Sen and Baltimore, 1986a,b; Gilman, et al., 1986; Angel, et al., 1987; Pierce, et al., 1988; Rauscher et al., 1988; Smeal, et al., 1989) and also be recognizable by specific antibodies. Over the past years, various protocols have been developed for the isolation of DNAs as well as the nuclear and cytoplasmic proteins which are involved in transcriptional modulation (Dignam et al., 1983a,b; Kadonaga and Tjian, 1986; Karpen, et al., 1988; Sambrook, et al., 1989; Fiering et al., 1990). However, the majority of these protocols require several steps of purification and high speed centrifugation which involves a significant time lapse between the collection of samples, and substantial physical contact with the laboratory workers. Moreover, the simultaneous isolation of DNAs and transcription factors is rather difficult in a short time span, which is an important aspect, for a sequential evaluation of gene modulation.

The following references define the present state of the art.

Angel, P. and Karin, M. 1991. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. *Biochim. Biophys. Acta.* 1072, 129.

Angel, P., Imagawa, M., Chiu, R., Stein, B., Imbra, R.J., Rahmsdorf, H.J., Joant, C., Herrlich, P., and Karin, M. 1987. Phorbol ester-inducible genes contain a common *cis* element recognized by a TPA-modulated *trans*-acting factor. *Cell* 49, 729.

Baldwin, A.S., Jr. 1996. The NF- κ B and I κ B proteins: new discoveries and insights. *Annu. Rev. Immunol.* 14, 649.

Banerjee, R., Bekesi, G.J., Tarcsafalvi, A., Sperber, K., Deak, G., Choi, H.S.H., Paronetto, F., Holland, J.F., and Acs, G. 1992. Productive nonlytic human immunodeficiency virus type 1 replication in a newly established human leukemia cell line. *Proc. Natl. Acad. Sci. USA* 89, 9996.

Banerjee, R., Karpen, S., Siekevitz, M., Lengyel, G., Bauer, J., and Acs, G. 1989. Tumor necrosis factor- α induces a kappa B sequence-specific DNA-binding protein in human hepatoblastoma HepG2 cells. *Hepatology* 10, 1008.

Bekesi, J.G., Banerjee, R., Jiang, J.D., Roboz, J.P., Tarcsafalvi, A., Holland, J.F., and Acs, G. 1995. Translocation of cytoplasmic antigenic markers in a biphenotypic cell line derived from a patient with myelodysplastic syndrome. *Mol. Cell. Diff.* 3, 111.

Caputo, A., Sodroski, J.G., and Haseltine, W.A. 1990. Constitutive expression of HIV-1 *tat* protein in human Jurkat T cells using a BK virus vector. *J. Acquired Immune Defic. Syndr.* 3, 372.

Crabtree, G.R. and Clipstone, N.A. 1994. Signal transmission between the plasma membrane and nucleus of T lymphocytes. *Annu. Rev. Biochem.* 63, 1045.

Crothers, D.M. 1987. Gel electrophoresis of protein-DNA complexes. *Nature* 325, 464.

Dignam, J.D., Lebovitz, R.M., and Roeder, R.G. 1983a. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. *Nucleic Acids Res.* 11, 1475.

Dignam, J.D., Martin, P.L., Shastry, B.S., and Roeder, R.G. 1983b. Eukaryotic gene transcription with purified components. *Methods Enzymol.* 101, 582.

Fiering, S., Northrop, J.P., Nolan, G.P., Mattila, P.S., Crabtree, G.R., and Herzenberg, L.A. 1990. Single cell assay of a transcription factor reveals a threshold in transcription activated by signals emanating from the T-cell antigen receptor. *Genes Dev.* 4, 1823.

Fried, M.G. 1989. Measurement of protein-DNA interaction parameters by electrophoresis mobility shift assay. *Electrophoresis* 10, 366.

Fried, M. and Crothers, D.M. 1981. Equilibria and kinetics of lac repressor-operator interactions by polyacrylamide gel electrophoresis. *Nucleic Acids Res.* 9, 6505.

Garner, M.M. and Revzin, A. 1981. A gel electrophoresis method for quantifying the binding of proteins to specific DNA regions: application to components of the *Escherichia coli* lactose operon regulatory system. *Nucleic Acids Res.* 9, 3047.

Garner, M.M. and Revzin, A. 1986. The use of gel electrophoresis to detect and study nucleic acid-protein interactions. *Trends in Biochem. Sci.* 11, 395.

Gilman, M.Z., Wilson, R.N., and Weinberg, R.A. 1986. Multiple protein-binding sites in the 5'-flanking region regulate *c-fos* expression. *Mol. Cell. Biol.* 6, 4305.

Innis, M.A., Gelfand, D.H., Sninsky, J.J., and White, T.J. 1990. PCR protocols: a guide to methods and applications. Academic Press. San Diego, CA.

Kadonaga, J.T. and Tjian, R. 1986. Affinity purification of sequence-specific DNA binding proteins. *Proc. Natl. Acad. Sci. USA* 83, 5889.

Karpen, S., Banerjee, R., Zelent, A., Price, P., and Acs, G. 1988. Identification of protein-binding sites in the hepatitis B virus enhancer and core promoter domains. *Mol. Cell. Biol.* 8, 5159.

Knowles, B.B., Howe, C.C., and Aden, D.P. 1980. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. *Science* 209, 497.

Lee, W., Mitchell, P., and Tjian, R. 1987. Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. *Cell* 49, 741.

Mitchell, P. J. and Tjian, R. 1989. Transcriptional regulation in mammalian cells by sequence-specific DNA binding protein. *Science* 245, 371.

Miyamoto, S. and Verma, I.M. 1995. Rel/NF- κ B/I κ B story. *Adv. Cancer Res.* 66, 255.

Northrop, J.P., Ullman, K.S., and Crabtree, G.R. 1993. Characterization of the nuclear and cytoplasmic components of the lymphoid-specific nuclear factor of activated T cells (NF-AT) complex. *J. Biol. Chem.* 268, 2917.

Piatak, M., Jr., Luk, K.C., Williams, B., and Lifson, J.D. 1993a. Quantitative competitive polymerase chain reaction for accurate quantitation of HIV DNA and RNA species. *Biotechniques* 14, 70.

Piatak, M., Jr., Saag, M.S., Yang, L.C., Clark, S.J., Kappes, J.C., Luk, K.C., Hahn, B.H., Shaw, G.M., and Lifson, J.D. 1993b. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. *Science* 259, 1749.

Pierce, J.W., Lenardo, M., and Baltimore, D. 1988. Oligonucleotide that binds nuclear factor NF- κ B acts as a lymphoid-specific and inducible enhancer element. Proc. Natl. Acad. Sci. USA 85, 1482.

Pizzella, T. and Banerjee, R. 1994. Identification of a human immunodeficiency virus type 1 TAR binding protein in human hepatoblastoma HepG2 cells that *trans*-activates HIV-1 LTR-directed gene expression. DNA Cell Bio. 13, 67.

Rao, A., Luo, C., and Hogan, P.G. 1997. Transcription factors of the NFAT family: regulation and function. Annu. Rev. Immunol. 15, 707.

Rauscher, F.J., III, Sambucetti, L.C., Curran, T., Distel, R.J., and Spiegelman, B.M. 1988. Common DNA binding site for Fos protein complexes and transcription factor AP-1. Cell 52, 471.

Saha, K., Sova, P., Chao, W., Chess, L., and Volsky, D.J. 1996. Generation of CD4⁺ and CD8⁺ T-cell clones from PBLs of HIV-1 infected subjects using herpesvirus saimiri. Nature Med. 2, 1272.

Sambrook, J., Fritsch, E.F., and Maniatis, T. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, NY.

Sen, R. and Baltimore, D. 1986a. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 46, 705.

Sen, R. and Baltimore, D. 1986b. Inducibility of κ immunoglobulin enhancer-binding protein NF- κ B by a posttranslational mechanism. Cell 47, 921.

Singh, H., Sen, R., Baltimore, D., and Sharp, P.A. 1986. A nuclear factor that binds to a conserved sequence motif in transcriptional control elements of immunoglobulin genes. Nature 319, 154.

Smeal, T., Angel, P., Meek, J., and Karin, M. 1989. Different requirements for formation of Jun:Jun and Jun:Fos complexes. Genes Dev. 3, 2091.

Starcich, B., Ratner, L., Josephs, S.F., Okamoto, T., Gallo, R.C., and Staal, F.W. 1985. Characterization of long terminal repeat sequences of HTLV-III. Science 227, 538.

Weiss, A., Wiskocil, R.L., and Stobo, J.D. 1984. The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL-2 production reflects events occurring at a pre-translational level. J. Immunol. 133, 123.

OBJECTS AND SUMMARY OF THE INVENTION

It is an object of the present invention to provide a rapid and efficient method for simultaneous isolation of biologically active transcription factors and DNA.

Another object of the present invention is to provide a method for simultaneous isolation of biologically active transcription factors and DNA which requires minimal handling of samples from the patients with various disease states and pathogenic conditions such as AIDS, hepatitis, and other infectious diseases, which require substantial precautions during isolation of DNAs and proteins.

Another object of the present invention is to provide a method for simultaneous isolation of biologically active transcription factors and DNA which is a fast and efficient way to prepare various cellular proteins.

Another object of the present invention is to provide a method for simultaneous isolation of biologically active transcription factors and DNA which permits multiple sample collection over a short time span for sequential analysis of gene activation.

Another object of the present invention is to provide a method for simultaneous isolation of biologically active transcription factors and DNA in which there is no requirement for expensive or specialized equipment such as ultracentrifuges or sonicators.

Another object of the present invention is to provide a method for simultaneous isolation of biologically active transcription factors and DNA in which physical contact and manipulation steps are minimized, providing additional safety in the preparation of samples from biologically hazardous infectious patients or cells treated with toxic chemical components.

Another object of the present invention is to provide an efficient method for sample collection from patients at various stages of their disease and to evaluate them at a desirable time to collect and analyze a comparative data.

Another object of the present invention is to provide a method for simultaneous isolation of biologically active transcription factors and DNA which is capable of isolating proteins and DNAs simultaneously from each sample so that it is possible to analyze the alterations in DNA modification as well as related changes in the transcriptional proteins. Isolation of RNAs can also be achieved by modifying this method.

Another object of the present invention is to provide a method for simultaneous isolation of biologically active transcription factors and DNA which provides major advantages over previously published protocols (Dignam et al., 1983a,b; Kadonaga and Tjian, 1986; Fiering et al., 1990; Pizzella and Banerjee, 1994) is that these extracts do not require either extensive manipulation after initial collection, or dialysis of the DNAs and proteins to remove salt or other contaminating reagents.

Yet another object of the present invention is to provide a method for simultaneous isolation of high purity biologically active transcription factors and DNA in which samples prepared by this method can be frozen quickly at -86 °C and then used later.

The foregoing and other objects and advantages of the present invention will appear more clearly hereinafter.

The following abbreviations will be used in the description of the present invention. AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency virus; TNF- α , tumor necrosis factor α ; PMA, phorbol 12-myristate 13-acetate; Br-cAMP, 8-bromo-adenosine 3':5'-

cyclic monophosphate; PBS, phosphate buffered saline; TAE, tris-acetate EDTA; TBE, tris-borate EDTA; FCS, fetal calf serum; DTT, dithiothreitol; PMSF, phenylmethylsulfonyl fluoride; EMSA, electrophoretic mobility shift assay; NF- κ B, nuclear factor κ B AP-1, activator protein.

In accordance with the present invention there is provided a rapid method for isolation of both transcription factors, also known as transcriptionally active proteins, and DNA without the use of any expensive high-speed centrifugation. Transcription factors play a crucial role in gene regulation during different stages of eukaryotic development as well as in controlling various cellular disorders involving the immune system. In order to study the role of cellular DNAs and the effects of certain biologically active regulatory proteins, which can affect gene expression, we have developed a rapid and efficient method for preparing highly purified DNAs as well as nuclear and cytoplasmic proteins, simultaneously. These DNAs and proteins can be effectively analyzed to determine their genetic integrity and binding motifs to specific DNA sequences, respectively. This protocol avoids the drastic use of mechanical shearing of cells, aggressive use of detergents or high speed ultracentrifugation steps, as well as facilitating the ease of collecting samples in a sequential and effective manner with minimal time lapse during processing. Such an approach permits the analysis of a large number of samples in a short time. The current technique uses a non-ionic detergent to isolate nuclei, and obtain the cytosolic extract, a low-ionic strength buffer to wash off the detergent and a high-salt buffer to extract nuclear proteins including transcription factors. The remainder of the cellular products are processed for DNA extraction. This method will be particularly useful to evaluate the time course effects of various cell signal transducing biological modifiers such as cytokines or mitogens, as well as drugs and other therapeutic agents

or adjuvants used in the treatments of various groups of patients, especially in infectious diseases and also in immunological or neoplastic disorders, with minimal physical contact to the laboratory personnel. This rapid DNA and protein isolation method can be widely used in various systems to analyze the modulation of DNA characteristics and transcriptionally active proteins as biomarkers in different human diseases.

DESCRIPTION OF THE DRAWINGS

Other important objects and advantages of the invention will be apparent from the following detailed description of the invention, taken in connection with the accompanying drawings in which:

Fig. 1. shows activation of NF- κ B (Lanes 2,3) and AP-1 (Lanes 9,10) in MDS cells following 4 h treatment with either TNF- α or PMA, as compared with the untreated controls (Lanes 1 and 8) which show the presence of low levels of constitutive NF- κ B and AP-1 in this cell line.

Fig. 2. is a super shift assay showing the expression of the NF- κ B (Lanes 1-10) or AP-1 (Lanes 11-20) protein subunits in MDS cells treated for 4 h with either TNF- α or PMA detected using specific antibodies as compared to the extracts without any antibody (Lanes 1-3 and 11-13).

Fig. 3. is an analysis of the DNA profile isolated from undifferentiated (Lanes 3-6) and differentiated (Lanes 7-10) MDS cells.

Fig 4. is a schematic flow chart outlining the method of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

With reference to the drawings, the present invention provides a rapid method modified from the previously published procedure (Karpen et al., 1988; Pizzella and Banerjee, 1994) that requires minimal time and effort and can be accomplished without the use of expensive high speed centrifugation. Furthermore, this method permits the isolation of both DNAs and transcription factors simultaneously from a wide range of lymphoid and non-lymphoid cells, either from the tissues or different organs of the patients, or the cells grown in culture from these tissues, without the loss of biological activity.

1. Advantages of the method according to the invention

A significant advantage of this method is that it entails minimal handling of samples from the patients with various disease states and pathogenic conditions such as AIDS, hepatitis, and other infectious diseases, which require substantial precautions during isolation of DNAs and proteins. The DNAs and transcription factors isolated by this method can be successfully used in various molecular assays such as Southern blot analyses, polymerase chain reaction (PCR) or restriction fragment length polymorphisms (RFLP) together with the DNA-protein interactions by electrophoretic mobility shift assays (EMSA), (Fried and Crothers, 1981; Garner and Revzin, 1981; Garner and Revzin, 1986; Crothers, 1987; Fried, 1989; Sambrook, et al., 1989; Innis, et al., 1990; Piatak, et al., 1993a,b; Pizzella and Banerjee, 1994). Using this rapid method we have specifically analyzed the DNA profile and the expression of two transcription factors, NF- κ B and AP-1, which are critical in the regulation of a number of genes and their activity is usually modified in different pathological conditions and disease states (Sen and Baltimore, 1986a,b; Lee, et al., 1987; Mitchell and Tjian, 1989; Angel and Karin, 1991; Miyamoto and Verma, 1995;

Baldwin, 1996). The isolation and characterization of the protein subunits of these transcription factors supports the efficacy and validity of this methodology.

2. Materials and methods

2.1 Cell lines

This isolation protocol has been examined using a number of lymphoid and non-lymphoid cell lines, including Jurkat-E6 (Weiss, et al., 1984), Jurkat-*tat* (Caputo, et al., 1990), HepG2 (Knowles, et al., 1980; Banerjee, et al., 1989) and various Herpesvirus transformed T cell-derived clones (HVS/TCC) from AIDS patients (Saha, et al., 1996). To develop this method, we have used a well characterized myeloid cell line, MDS, (Banerjee et al., 1992; Bekesi et al., 1995) which was derived from a patient with myelodysplastic syndrome and can be differentiated to lymphoid lineage by treatment with PMA (phorbol 12-myristate 13-acetate) together with Br-cAMP (8-bromo-adenosine 3':5'-cyclic monophosphate). MDS cells were maintained at a concentration of 2×10^5 /ml in Minimal Essential Medium (MEM) with 10% fetal calf serum (FCS), and antibiotics (penicillin-100 units/ml and streptomycin-100 μ g/ml) in 5% CO₂ at 37 °C. Cell culture reagents were purchased from GIBCO/BRL, Grand Island, NY.

2.2 Cell treatment and collection

MDS cells were treated either with TNF- α , (tumor necrosis factor- α , 200 units/ml, Genzyme, Cambridge, MA), PMA, (20 ng/ml, Sigma Chemical Co., St. Louis, MO) or PMA (20 ng/ml) combined with Br-cAMP, (200 μ g/ml, Sigma Chemical Co., St. Louis, MO) for 48 h to ensure differentiation to a lymphoid lineage (Banerjee et al., 1992). Various other cell signaling agents, therapeutic drugs, test compounds and carcinogens has also been used for testing the effectiveness of this method. For each sample, nuclear and cytoplasmic extracts

004050-2056560

were prepared from 1×10^7 cells, which were collected by centrifuging at 1,000 rpm for 5 min in a table top centrifuge and then washing the cell pellets twice with 5 ml ice cold PBS, (phosphate buffered saline, pH 7.4) and centrifuging the cells again at 1,000 rpm. The cell pellets were resuspended and transferred to an Eppendorf tube in 1 ml of ice cold PBS and then centrifuged at 2,000 rpm for 5 min at 4 °C. The PBS was removed completely and the cell pellets processed according to the protein and DNA isolation steps described in Sections 2.4 and 2.5. It should be emphasized that monolayer culture cells or macrophages which adhere to cell plates should be collected by using a rubber policeman and gentle tapping but not by trypsinization which degrades the protein moieties.

2.3 Reagent preparation

Buffer solutions:

(a): Buffer A: (cell lysis buffer), [20 mM Hepes, pH 7.9, 10 mM NaCl, 3 mM $MgCl_2$, 0.1% NP-40, 10% glycerol, 0.2 mM EDTA, 1 mM dithiothreitol (DTT), 0.4 mM phenylmethylsulfonyl fluoride (PMSF), antipain (1 μ g/ml), leupeptin (1 μ g/ml)].

(b): Buffer B: (extraction buffer without salt), [20 mM Hepes, pH 7.9, 0.2 mM EDTA, 20% glycerol, 1 mM DTT, 0.4 mM PMSF, antipain (1 μ g/ml), leupeptin (1 μ g/ml)].

(c): Buffer C: (extraction buffer with salt), [20 mM Hepes, pH 7.9, 400 mM NaCl, 0.2 mM EDTA, 20% glycerol, 1 mM DTT, 0.4 mM PMSF, antipain (1 μ g/ml), leupeptin (1 μ g/ml)].

(d): Buffer D: (cytoplasmic extraction clarification buffer), [20 mM Hepes, pH 7.9, 400 mM NaCl, 0.2 mM EDTA, 40% glycerol, 1 mM DTT, 0.4 mM PMSF, antipain (1 μ g/ml), leupeptin (1 μ g/ml)].

2.4 Simultaneous isolation of protein and DNA

The cell pellets were resuspended in about 100-125 μ l (2 pellet vol) of Buffer A and left on ice for 10-15 min with occasional tapping. The nuclei were pelleted by centrifuging at 2,000 rpm for 5 min at 4 °C. The cytoplasmic supernatant fraction was removed to another Eppendorf tube and "snap (quick) frozen" on dry ice and then put into a -86 °C freezer for storage. The nuclei were washed with 200-350 μ l Buffer B to remove NP-40 and centrifuged at 2,000 rpm for 5 min at 4 °C. The pelleted nuclei were then resuspended into 100-130 μ l Buffer C on ice for 45 min with periodic mixing by tapping to extract the nuclear proteins. The nuclear fraction was then centrifuged in an Eppendorf centrifuge at 13,000 rpm for 15 min at 4 °C. The supernatants were removed, aliquoted, and quick frozen on dry ice and stored at -86 °C. The remaining pellet containing nucleic acids and other debris was also snap frozen and stored at -86 °C or prepared immediately for DNA extraction as described below. If it is necessary to analyze the cytoplasmic fraction for detailed evaluation, it is further clarified by adding 1/3 vol of Buffer D to this fraction for 30 min at 4 °C to equilibrate the cytoplasmic proteins with NaCl, followed by centrifuging at 13,000 rpm for 15 min. The supernatants were snap frozen and stored at -86 °C.

2.5 DNA extraction and analysis

Frozen cell pellets from undifferentiated and differentiated MDS cells were thawed on ice for 10 min and then 100 μ l of Buffer A [0.1 % SDS, 10 mM Tris-HCl, pH 7.9, 10 mM EDTA, 10 mM NaCl] was added for 15 min and mixed using wide bore Eppendorf pipet tips. RNAase A [Boehringer Mannheim, Indianapolis, IN, 100 μ g/ml] was added for 2 h at 37 °C with gentle tapping every 30 min. Then proteinase K was added [Boehringer Mannheim, 200

004080-2605660

µg/ml] for 2 h at 37 °C with gentle tapping every 30 min followed by extraction with an equal volume of TE (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) saturated phenol. The upper aqueous layer was removed to another tube and back extractions were performed twice with 50 µl of TE and the DNA solutions were collected in a fresh tube. An equal volume of phenol/chloroform (50:50) mixture was added, mixed by inverting repeatedly, then centrifuged at 3,000 rpm for 10 min. The upper aqueous phase was removed, and then extracted with an equal volume of chloroform/isoamyl (96:4) alcohol and the resulting upper aqueous phase containing the DNA was precipitated using 0.5 M NaCl and 3 vol of ice cold ethanol at -20 °C. The samples were centrifuged at 13,000 rpm for 30 min, the DNA pellets were air dried, and dissolved in 300 µl of 0.1X TE at 37 °C for 4-6 h. If required, the DNA pellets can be dissolved in a warm room on a slow speed shaker overnight to facilitate solubilization.

Ten µg of the high molecular weight DNA from each sample were digested for 4 h with 30 units each of the three restriction enzymes, *EcoR* I, *BamH* I, and *Hind* III (New England Biolabs, Beverly, MA), and then electrophoresed on a 0.8% TAE (0.40 M Tris-acetate, 1 mM EDTA) agarose gel. The DNA gel was stained with ethidium bromide and photographed with UV light.

2.6 Radiolabeling of the sequence specific oligonucleotides

Single stranded oligonucleotides synthesized on a DNA synthesizer were annealed with the complimentary strand by combining 4 µg of both strands in a total volume of 30 µl of annealing buffer (5 mM NaCl, 10 mM Tris-HCl and 0.2 mM EDTA) and boiling the tubes for 5 min in 500 ml of water and slowly cooling to room temperature for 6 h. The tubes were then heated to 55 °C for 5 min and then chilled on ice for 10 min. A 4 µl aliquot of the annealed

oligos were quantitated at 260 λ and the remainder was stored at -20 °C until radiolabeled. The probes were prepared by radiolabeling 200 ng of annealed oligonucleotide in 15 μ l of total volume containing 50 μ Ci of [γ -³²P]ATP (6,000 Ci/mmol, New England Nuclear-DuPont, Boston, MA), 20 Units of T4 polynucleotide kinase (New England Biolabs, Beverly, MA), and 1.5 μ l 10X T4 polynucleotide kinase buffer (NEB, Beverly, MA) for 1 h at 37 °C, followed by filling in the 5' over-hang ends with 5 Units of Klenow (NEB, Beverly, MA) with 3.0 μ l of 10X Klenow buffer (NEB, Beverly, MA), and 0.15 mM each of dATP, dCTP, dGTP, and dTTP (Boehringer Mannheim, Indianapolis, IN), for 40 min at 37 °C in a reaction volume of 30 μ l. The volume was increased to 1 ml with sterile TE with 200 mM NaCl, pH 8.0, and the labeled oligonucleotides were purified on a NACS Prepac column (Life Technologies, Rockville, MD) following the manufacturer's instructions to separate the unincorporated nucleotides. The labeled, purified oligonucleotides were precipitated overnight with 3 vol absolute ethanol at -20 °C, centrifuged at 13,000 rpm for 1 h and then vacuum dried. The labeled oligonucleotide probes were resuspended in 100 μ l of sterile 0.1X TE buffer and stored at -20 °C.

2.7 Electrophoretic mobility shift assay

Electrophoretic mobility shift assays (EMSA) with nuclear protein extracts and radiolabeled NF- κ B and AP-1 probes were performed using a previously published protocol (Karpen et al., 1988; Banerjee et al., 1989; Pizzella and Banerjee, 1994) with certain modifications. Briefly, 5 μ g of nuclear extract was used for each reaction with 0.2-0.3 ng of [γ -³²P]ATP labeled oligonucleotide probe containing either NF- κ B sequence (Starcich et al., 1985) from HIV-1 LTR (5'-gatccGGGACTTTCCGCTGGGGACTTTCCG-3') or an AP-1

consensus sequence (Northrop et al., 1993) including the PMA responsive element indicated in bold (5'-gatcc**GTGACTCAGCGCG**-3'). For each DNA-protein binding reaction 3 µg of poly(dI-dC):poly(dI-dC) was used as a non-specific competitor and incubated with the nuclear extracts for 10 min prior to the addition of the radiolabeled probe. For supershift assays, antibodies against p65, p50, *c-Fos* or *c-Jun* (Santa Cruz Biotechnology, Santa Cruz, CA) were added to the respective binding reactions and incubated at room temperature for 1.5 h, prior to probing with [γ -³²P]ATP labeled oligonucleotide for an additional 25 min at room temperature. The bound complexes were separated on either a 5% or 6% acrylamide/bis (30:1 ratio) native gel as required and run at 200v for 3.5 h with 0.25X TBE (0.02 M Tris-borate, 0.5 mM EDTA) as running buffer at room temperature and then vacuum dried with heat at 80 °C and exposed to Kodak X-OMAT film (Eastman Kodak, Rochester, NY). Specifically, the 5% gels were used for assays that included antibodies for optimal separation of the bound protein complexes, whereas, 6% gels were critical for resolving various specific and non-specific bands more precisely.

3. Results

3.1 Activation of NF- κ B and detection of its p65 and p50 subunits

Using this rapid protein isolation method we successfully demonstrated the binding of MDS nuclear extracts to the radiolabeled NF- κ B probe in an EMSA (Figs. 1,2). Cells were treated with TNF- α or PMA for 4 h to stimulate activation of NF- κ B complex as compared to untreated MDS cells used as a control. The activation of NF- κ B with either TNF- α or PMA treatment was about 8 and 10 fold, respectively, as compared to the untreated control (Fig. 1, Lanes 1-3). The high level of activation by both TNF- α and PMA in a short treatment period correlated well with the data obtained using other protocols (data not shown). Competition

EMSA with a 50-fold molar excess of unlabeled oligonucleotide as competitor demonstrated the specificity of binding for NF- κ B probes (Fig. 1, Lanes 4-6).

In order to demonstrate that the different components of transcription factors isolated by this method are intact in this extract and can be recognized by their specific antibodies, we have performed supershift assays to illustrate the presence of p65 (Rel A) and p50 (NF- κ B1) in the NF- κ B binding complexes. The bound complex observed in Fig. 1 contained both p65 and p50 fractions for both TNF- α and PMA treated extracts. The shifted fractions contained a much higher amount of p65 complex (I) as compared to p50 for both TNF- α and PMA treated cell extracts (Fig. 2, Lanes 5,6 and 8,9, respectively). Although no p50 complex (II) was visible, a reduction of bound complex (III) due to the reaction with p50 specific antibody substantiates the presence of this complex in these extracts (Fig. 2, Lanes 8,9). The distinct presence of p65 band (I) with TNF- α or PMA, and a reduction of bound band (III) with p50 antibody on the gel (Fig. 2), indicated that there was no significant damage to the proteins present in the complex and, importantly, no formation of aggregation during preparation.

3.2 Activation of AP-1 and identification of the Fos and Jun complexes

The binding of nuclear extracts from TNF- α or PMA treated cells to a radiolabeled AP-1 consensus sequence probe was analyzed by an EMSA. In addition to the NF- κ B activation the level of AP-1 induced by 4 h of PMA treatment was very high compared to the untreated control or TNF- α treated sample (Fig. 1, Lanes 8-10). Although AP-1 activation due to 4 h of TNF- α treatment was much lower than that observed following PMA treatment, it was slightly higher than the untreated control as resolved in the 5% gel (Fig. 2, Lanes 11-13), thus

indicating the validity of using two different gel compositions for specific purposes. The competition EMSAs with a 50-fold molar excess of unlabeled AP-1 oligonucleotide showed the specificity of this binding (Fig. 1, Lanes 11-13). These results clearly demonstrate that transcription factors prepared by this technique can accurately bind to their respective specific sequence motifs.

In order to demonstrate the various components of the AP-1 complex, namely, *c-Fos* and *c-Jun*, the nuclear extracts were analyzed by supershift assays by incubating with antibodies against *c-Fos* and *c-Jun*. Both TNF- α and PMA treated samples showed the presence of *c-Fos* and *c-Jun* epitopes since the bound complexes present in the corresponding antibody treated lanes (Fig. 2, Lanes 14-19) were significantly reduced as compared to the untreated samples (Fig 2., Lanes 11-13). Specifically, a strongly shifted complex due to *c-Fos* antibody was revealed only in the PMA treated sample (Fig. 2, Lane 16), whereas TNF- α treated samples had significantly reduced bands for both *c-Fos* and *c-Jun*, as compared to the TNF- α treated extract without antibody (Fig. 2, Lanes 12, 15 and 18). It is evident that the binding epitopes for *c-Fos* and *c-Jun* remain intact throughout processing of the cell samples and during the assay to detect binding activity.

3.3 Analysis of the DNA profile

The undigested DNA profile of the undifferentiated MDS cells (Fig. 3, Lane 3) or MDS cells differentiated for 48 h (Fig. 3, Lane 7) showed that there was no degradation of the DNAs during processing in either of these samples and that their molecular weight was higher than 23kb. These DNAs were completely digested with *EcoR* I, *BamH* I, or *Hind* III, respectively, (Lanes 4-

6 and 8-10) indicating that these samples are free from protein and other contaminants and can optimally recognize the specificity of these restriction enzymes.

Examples of the results obtained through the use of the method of the present invention are shown in Figs. 1-3. An overall schematic flowchart outlining the method of the present invention is shown in Fig. 4.

Fig. 1. shows activation of NF- α B (Lanes 2,3) and AP-1 (Lanes 9,10) in MDS cells following 4 h treatment with either TNF- α or PMA, as compared with the untreated controls (Lanes 1 and 8) which show the presence of low levels of constitutive NF- κ B and AP-1 in this cell line. Nuclear extracts were incubated with either a [γ - 32 P]ATP radiolabeled NF- κ B or AP-1 probe for 25 min and the bound complexes were resolved on a 6% native gel for EMSA as described in the Materials and Methods. The specificity of binding to the respective probes was determined using a 50-fold molar excess of either NF- κ B (Lanes 4-6) or AP-1 (Lanes 11-13) unlabeled oligonucleotide as competitors which completely removed all the binding, indicating that these bound complexes resulted from the sequence specific DNA-protein interactions. The arrows indicate the induced NF- κ B (I) and the AP-1 (III) complexes, respectively, whereas, the constitutive bands (II) and as well as unbound free probe (FP) resulting from the NF- κ B (Lane 7) or AP-1 (Lane 14) are also shown.

Fig. 2. is a super shift assay showing the expression of the NF- κ B (Lanes 1-10) or AP-1 (Lanes 11-20) protein subunits in MDS cells treated for 4 h with either TNF- α or PMA detected using specific antibodies as compared to the extracts without any antibody (Lanes 1-3 and 11-13). Nuclear extracts were treated for 1.5 h with antibodies before probing with [γ -

³²P]ATP labeled NF-κB or AP-1, and the complexes were resolved by EMSA on a 5% native gel as described in the Materials and Methods. The extracts were incubated with the antibody against NF-κB p65 subunit (Lanes 4-6) showing the shifted complex (I, Lanes 5,6). A reduced bound (III) and a slightly shifted complex (II, Lanes 8,9) were observed with p50 antibody treatment. The presence of *c-Fos* complex, (Lanes 14-16) and *c-Jun* (Lanes 17-19) were demonstrated mainly by the reduction of the bound complexes (V) and a major shifted *c-Fos* band due to the PMA treatment (IV, Lane 16). Unbound free probe (FP) is also shown for NF-κB (Lane 10) and AP-1 (Lane 20) at the bottom of the gel.

Fig. 3. is an analysis of the DNA profile isolated from undifferentiated (Lanes 3-6) and differentiated (Lanes 7-10) MDS cells. DNA (10 µg per lane) was digested with *EcoR* I, *BamH* I or *Hind* III, (Lanes 4-6, and Lanes 8-10) and compared with the corresponding undigested controls (Lanes 3 and 7) following analysis on a 0.8% TAE agarose gel. Two µg of *Hae* III digest ΦX174 and *Hind* III digest λ DNAs were used as molecular size markers (Lanes 1,2), respectively, ranging from 23.1 to 0.56kb.

Fig. 4. shows an overall schematic flowchart of the method according to the present invention.

4. Discussion

This report describes an improved method for preparing samples of both nuclear and cytoplasmic extracts (data not shown) which is rapid and can be efficiently used in EMSAs with specific DNA sequences. This method offers significant advantages over other published protocols: (1) it is a fast and efficient way to prepare various cellular proteins; (2) it permits multiple sample collection over a short time span for sequential analysis of gene activation; (3)

there is no requirement for expensive or specialized equipment such as ultracentrifuges or sonicators; (4) physical contact and manipulation steps are minimized, providing additional safety in the preparation of samples from biologically hazardous infectious patients or cells treated with toxic chemical components; and (5), most importantly, this method is capable of isolating proteins and DNAs simultaneously from each sample so that it is possible to analyze the alterations in DNA modification as well as related changes in the transcriptional proteins.

The only major requirements for this procedure are a few buffers, some common reagents and supplies, and an Eppendorf type centrifuge at 4 °C. This procedure can be carried out in most research or clinical laboratories. In addition, the protein concentrations of these extracts are usually high enough so that they can be diluted several fold before use in an EMSA. Furthermore, one of the major advantages over previously published protocols (Dignam et al., 1983a,b; Kadonaga and Tjian, 1986; Fiering et al., 1990; Pizzella and Banerjee, 1994) is that these extracts do not require either extensive manipulation after initial collection, or dialysis of the DNAs and proteins to remove salt or other contaminating reagents. The samples prepared at multiple time points offers the advantage that they are processed in the same experimental set up in a short time span which is extremely critical in isolating activated transcription factors from various disease states and pathological conditions. The results showed that highly purified intact proteins and DNAs are obtained by this method (Figs. 1-3) and are comparable to the results obtained using more elaborate protocols (Dignam, et al., 1983a,b; Sen and Baltimore, 1986a,b; Sambrook, et al., 1989). This procedure also permits the isolation with full biological activity of critical cellular factors involved in gene regulation but which have short half-lives. Another major advantage we have observed is that most of the samples prepared by this method can be frozen quickly at -86 °C

and then used more than a year later. Furthermore, the samples are capable of withstanding several freeze-thaw cycles without any noticeable changes or degradation in the level of binding to different radiolabeled probes for a prolonged time. Although we have demonstrated this improved technique using the MDS cell line, we have also prepared samples from various other lymphoid cells, including cells from HIV-1 infected patients and also non-lymphoid cells with equally effective and reproducible results. For example, in the case of human hepatoblastoma HepG2 cells in addition to NF- κ B expression following TNF- α treatment (Banerjee, et al., 1989), there was also a strong induction of AP-1 binding with both TNF- α and PMA treatments, and the complexes revealed the expression of both *c-Fos* and *c-Jun* subunits (data not shown), which is slightly different from the results obtained from the MDS cells. Furthermore, there was no significant difference in the DNA profile among the undifferentiated and differentiated MDS cells, but we have observed certain changes in the EMSA data among these two groups, which will be published elsewhere. Therefore, this simplified and efficient method will prove applicable and extremely helpful in numerous clinical as well as experimental situations for the analysis of DNA profiles and transcriptional activation. Moreover, the major advantage of this method is to provide the ease of collecting samples, during multiple stages of evaluation, and analyzing them with a nominal variation at a later time. Furthermore, this isolation method will allow to extract RNAs (ribonucleic acids) as an intermediary product which is also provides an additional advantage. Therefore, this method has proven significant advantage over other protocols being used where all these three basic biological components, namely DNA, RNA and protein, are purified.

With reference to figure 4 the Methods for simultaneous isolation of biologically active transcription factors and DNA includes the following steps which are illustrated schematically in Figure 4.

- 1 Collecting and maintaining cells at a concentration in the range of $1-2 \times 10^5/\text{ml}$ in culture medium,
- 2 Treating cells with at least one test compound or obtaining the cells from the treated patients,
- 3 Collecting the cells by scrapping and by centrifuging at 1,000 rpm for 5 min in a table top centrifuge,
- 4 Washing the cell pellets twice with 5 ml ice cold PBS, (phosphate buffered saline, pH 7.4) by centrifuging the cells again at 1,000 rpm,
- 5 Resuspending the cell pellets, transferring to a first Eppendorf tube in 1 ml of ice cold PBS,
- 6 Centrifuging at 2,000 rpm for 5 min at 4 °C removing the PBS processing the cell pellets following according to the protein and DNA isolation steps comprising,
- 7 Preparing Buffer A: (cell lysis buffer), [20 mM Hepes, pH 7.9, 10 mM NaCl, 3 mM MgCl_2 , 0.1% NP-40, 10% glycerol, 0.2 mM EDTA, 1 mM dithiothreitol (DTT), 0.4 mM phenylmethylsulfonyl fluoride (PMSF), antipain (1 $\mu\text{g}/\text{ml}$), leupeptin (1 $\mu\text{g}/\text{ml}$)],
- 8 Preparing Buffer B: (extraction buffer without salt), [20 mM Hepes, pH 7.9, 0.2 mM EDTA, 20% glycerol, 1 mM DTT, 0.4 mM PMSF, antipain (1 $\mu\text{g}/\text{ml}$), leupeptin (1 $\mu\text{g}/\text{ml}$)],
- 9 Preparing Buffer C: (extraction buffer with salt), [20 mM Hepes, pH 7.9, 400 mM NaCl, 0.2 mM EDTA, 20% glycerol, 1 mM DTT, 0.4 mM PMSF, antipain (1 $\mu\text{g}/\text{ml}$), leupeptin (1 $\mu\text{g}/\text{ml}$)],

- 10 Preparing Buffer D: (cytoplasmic extraction clarification buffer), [20 mM Hepes, pH 7.9, 400 mM NaCl, 0.2 mM EDTA, 40% glycerol, 1 mM DTT, 0.4 mM PMSF, antipain (1 μ g/ml), leupeptin (1 μ g/ml)],
- 11 Performing Simultaneous isolation of protein and DNA comprising the steps of,
- 12 Resuspending the cell pellets in 100-125 μ l (2 pellet vol) of Buffer A,
- 13 Maintaining the resuspended cell pellets on ice for 10-15 min with occasional tapping,
- 14 Pelleting the nuclei by centrifuging at 2,000 rpm for 5 min at 4 $^{\circ}$ C,
- 15 Removing the cytoplasmic supernatant fraction to a second Eppendorf tube,
- 16 Quick freezing on dry ice in a -86 $^{\circ}$ C freezer and store for future use,
- 17 Washing the bottom nuclear fraction with 200-300 μ l Buffer B to remove NP-40,
- 18 Centrifuging at 2,000 rpm for 5 min at 4 $^{\circ}$ C,
- 19 Resuspending the pelleted nuclei into 100-130 μ l high salt Buffer C on ice for 45 min and mixing periodically by tapping to extract the nuclear proteins,
- 20 Centrifuging the nuclear fraction in an Eppendorf centrifuge at 13,000 rpm for 15 min at 4 $^{\circ}$ C,
- 21 Removing the supernatants, aliquoted, in 25 μ l and quick freezing on dry ice,
- 22 Storing at -86 $^{\circ}$ C,
- 23 Quick freezing the remaining pellet containing nucleic acids and other debris,
- 24 Storing at -86 $^{\circ}$ C,
- 25 Clarifying the cytoplasmic fraction by adding 1/3 vol of Buffer D to this fraction for 30 min at 4 $^{\circ}$ C to equilibrate the cytoplasmic proteins with NaCl,
- 26 Centrifuging at 13,000 rpm for 15 min.,

- 27 Removing and quick freezing the supernatants and storing at -86°C ,
- 28 Performing DNA extraction and analysis comprising the steps of,
- 29 Thawing frozen cell pellets from on ice for 10 min,
- 30 Adding 100 μl of Buffer [0.1 % SDS, 10 mM Tris-HCl, pH 7.9, 10 mM EDTA, 10 mM NaCl] for 15 min,
- 31 Mixing using wide bore Eppendorf pipet tips,
- 32 Adding RNAase A for 2 h at 37°C with gentle tapping every 30 min,
- 33 Adding proteinase K [200 μl /ml] for 2 h at 37°C with gentle tapping every 30 min,
- 34 Extracting with an equal volume of TE (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) saturated phenol,
- 35 Removing the upper aqueous layer was removed to another tube,
- 36 Performing back extractions twice with 50 μl of TE,
- 37 Collecting the DNA solutions in a fresh tube,
- 38 Adding an equal volume of phenol/chloroform (50:50) mixture,
- 39 Mixing by inverting repeatedly,
- 40 Centrifuging at 3,000 rpm for 10 min,
- 41 Removing the upper aqueous phase,
- 42 Extracting with an equal volume of chloroform/isoamyl (96:4) alcohol,
- 43 Removing the upper aqueous phase containing the DNA and precipitating using 0.5 M NaCl and 3 vol of ice cold ethanol at -20°C ,
- 44 Centrifuging the samples at 13,000 rpm for 30 min,
- 45 Air drying the DNA pellets,

- 46 Dissolving DNA in 300 μ l of 0.1X TE at 37 °C for 4-6 h,
- 47 Digesting ten μ l of the high molecular weight DNA from each sample for 4 h with 30 units of restriction enzymes,
- 48 Electrophoresing on a 0.8% TAE (0.40 M Tris-acetate, 1 mM EDTA) agarose gel,
- 49 Staining the DNA gel with ethidium bromide,
- 50 Photographing with UV light,
- 51 Radiolabeling of the sequence specific oligonucleotides comprising the steps of,
- 52 Synthesizing single stranded oligonucleotides on a DNA synthesizer and annealing with the complimentary strand by combining 4 μ g of both strands in a tube with total volume of 30 μ l of annealing buffer (5 mM NaCl, 10 mM Tris-HCl and 0.2 mM EDTA),
- 53 boiling the tubes for 5 min and slowly cooling to room temperature for 6 h,
- 54 Heating the tubes to 55 °C for 5 min and then cooling on ice for 10 min,
- 55 Quantitating 4 μ l aliquot of the annealed oligos at 260 λ and storing the remainder at -20 °C until radiolabeled,
- 56 Preparing probes by radiolabeling 200 ng of annealed oligonucleotide in 15 μ l of total volume containing 50 μ Ci of [γ -³²P]ATP (6,000 Ci/mmol), 20 Units of T4 polynucleotide kinase, and 1.5 μ l 10X T4 polynucleotide kinase buffer for 1 h at 37 °C,
- 57 Filling in the 5' over-hang ends with 5 Units of Klenow with 3.0 μ l of 10X Klenow buffer and 0.15 mM each of dATP, dCTP, dGTP, and dTTP for 40 min at 37 °C in a reaction volume of 30 μ l.

- 58 Increasing the volume to 1 ml with sterile TE with 200 mM NaCl, pH 8.0, and the labeled oligonucleotides were purified on a NACS Prepac column, to separate the unincorporated nucleotides,
- 59 Precipating the labeled, purified oligonucleotides overnight with 3 vol absolute ethanol at -20 °C,
- 60 Centrifuging at 13,000 rpm for 1 h and then vacuum drying,
- 61 Resuspending the labeled oligonucleotide probes in 100 µl of sterile 0.1X TE buffer and storing at -20 °C,
- 62 Electrophoretic mobility shift assay,
- 63 Incubating 5 µg of nuclear or cytoplasmic extract, for each reaction, with 0.2-0.3 ng of [γ - 32 P]ATP labeled oligonucleotide probe containing either NF- κ B sequence (5'-gatccGGGACTTTCCGCTGGGGACTTTCCG-3') or an AP-1 consensus sequence including the PMA responsive element indicated in bold (5'-gatcc**GTGACTCAGCGCG**-3'),
- 64 Adding 3 µg of poly(dI-dC):poly(dI-dC) as a non-specific competitor and incubating with the nuclear extracts for 10 min prior to the addition of the radiolabeled probe,
- 65 Adding antibodies against p65, p50, *c-Fos* or *c-Jun* to the respective binding reactions for supershift assays and incubating at room temperature for 1.5 h, prior to probing with [γ - 32 P]ATP labeled oligonucleotide for an additional 25 min at room temperature,
- 66 Separating the bound complexes on either a 5% ,for supershift assays, or 6% ,for analytical purposes, acrylamide/bis (30:1 ratio) native gel as required and running at 200v for 3.5 h with 0.25X TBE (0.02 M Tris-borate, 0.5 mM EDTA) as running buffer at room temperature,

67 Vacuum drying the gel with heat at 80 °C and exposing them to Kodak X-OMAT film for 3-12 hours,

68 Analyzing the bound and free DNA protein complexes.

The foregoing specific embodiments of the present invention as set forth in the specification herein are for illustrative purposes only. Various deviations and modifications may be made within the spirit and scope of the this invention without departing from the main theme thereof.

WHAT IS CLAIMED IS:

Method for simultaneous isolation of biologically active transcription factors and DNA comprising the steps of:

- 1 Collecting and maintaining cells at a concentration in the range of $1-2 \times 10^5$ /ml in culture medium,
- 2 Treating cells with at least one test compound or obtaining the cells from the treated patients,
- 3 Collecting the cells by scrapping and by centrifuging at 1,000 rpm for 5 min in a table top centrifuge,
- 4 Washing the cell pellets twice with 5 ml ice cold PBS, (phosphate buffered saline, pH 7.4) by centrifuging the cells again at 1,000 rpm,
- 5 Resuspending the cell pellets, transferring to a first Eppendorf tube in 1 ml of ice cold PBS,
- 6 Centrifuging at 2,000 rpm for 5 min at 4 °C removing the PBS processing the cell pellets following according to the protein and DNA isolation steps comprising,
- 7 Preparing Buffer A: (cell lysis buffer), [20 mM Hepes, pH 7.9, 10 mM NaCl, 3 mM MgCl₂, 0.1% NP-40, 10% glycerol, 0.2 mM EDTA, 1 mM dithiothreitol (DTT), 0.4 mM phenylmethylsulfonyl fluoride (PMSF), antipain (1 µg/ml), leupeptin (1 µg/ml)],
- 8 Preparing Buffer B: (extraction buffer without salt), [20 mM Hepes, pH 7.9, 0.2 mM EDTA, 20% glycerol, 1 mM DTT, 0.4 mM PMSF, antipain (1 µg/ml), leupeptin (1 µg/ml)],
- 9 Preparing Buffer C: (extraction buffer with salt), [20 mM Hepes, pH 7.9, 400 mM NaCl, 0.2 mM EDTA, 20% glycerol, 1 mM DTT, 0.4 mM PMSF, antipain (1 µg/ml), leupeptin (1 µg/ml)],

- 10 Preparing Buffer D: (cytoplasmic extraction clarification buffer), [20 mM Hepes, pH 7.9, 400 mM NaCl, 0.2 mM EDTA, 40% glycerol, 1 mM DTT, 0.4 mM PMSF, antipain (1 μ g/ml), leupeptin (1 μ g/ml)],
- 11 Performing Simultaneous isolation of protein and DNA comprising the steps of,
- 12 Resuspending the cell pellets in 100-125 μ l (2 pellet vol) of Buffer A,
- 13 Maintaining the resuspended cell pellets on ice for 10-15 min with occasional tapping,
- 14 Pelleting the nuclei by centrifuging at 2,000 rpm for 5 min at 4 °C,
- 15 Removing the cytoplasmic supernatant fraction to a second Eppendorf tube,
- 16 Quick freezing on dry ice in a -86 °C freezer and store for future use,
- 17 Washing the bottom nuclear fraction with 200-300 μ l Buffer B to remove NP-40,
- 18 Centrifuging at 2,000 rpm for 5 min at 4 °C,
- 19 Resuspending the pelleted nuclei into 100-130 μ l high salt Buffer C on ice for 45 min and mixing periodically by tapping to extract the nuclear proteins,
- 20 Centrifuging the nuclear fraction in an Eppendorf centrifuge at 13,000 rpm for 15 min at 4 °C,
- 21 Removing the supernatants, aliquoted, in 25 μ l and quick freezing on dry ice,
- 22 Storing at -86 °C,
- 23 Quick freezing the remaining pellet containing nucleic acids and other debris,
- 24 Storing at -86 °C,
- 25 Clarifying the cytoplasmic fraction by adding 1/3 vol of Buffer D to this fraction for 30 min at 4 °C to equilibrate the cytoplasmic proteins with NaCl,
- 26 Centrifuging at 13,000 rpm for 15 min.,

- 27 Removing and quick freezing the supernatants and storing at -86 °C,
- 28 Performing DNA extraction and analysis comprising the steps of,
- 29 Thawing frozen cell pellets from on ice for 10 min,
- 30 Adding 100 μ l of Buffer [0.1 % SDS, 10 mM Tris-HCl, pH 7.9, 10 mM EDTA, 10 mM NaCl] for 15 min,
- 31 Mixing using wide bore Eppendorf pipet tips,
- 32 Adding RNAase A for 2 h at 37 °C with gentle tapping every 30 min,
- 33 Adding proteinase K [200 μ l/ml] for 2 h at 37 °C with gentle tapping every 30 min,
- 34 Extracting with an equal volume of TE (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) saturated phenol,
- 35 Removing the upper aqueous layer was removed to another tube,
- 36 Performing back extractions twice with 50 μ l of TE,
- 37 Collecting the DNA solutions in a fresh tube,
- 38 Adding an equal volume of phenol/chloroform (50:50) mixture,
- 39 Mixing by inverting repeatedly,
- 40 Centrifuging at 3,000 rpm for 10 min,
- 41 Removing the upper aqueous phase,
- 42 Extracting with an equal volume of chloroform/isoamyl (96:4) alcohol,
- 43 Removing the upper aqueous phase containing the DNA and precipitating using 0.5 M NaCl and 3 vol of ice cold ethanol at -20 °C,
- 44 Centrifuging the samples at 13,000 rpm for 30 min,
- 45 Air drying the DNA pellets,

- 46 Dissolving DNA in 300 μ l of 0.1X TE at 37 °C for 4-6 h,
- 47 Digesting ten μ l of the high molecular weight DNA from each sample for 4 h with 30 units of restriction enzymes,
- 48 Electrophoresing on a 0.8% TAE (0.40 M Tris-acetate, 1 mM EDTA) agarose gel,
- 49 Staining the DNA gel with ethidium bromide,
- 50 Photographing with UV light,
- 51 Radiolabeling of the sequence specific oligonucleotides comprising the steps of,
- 52 Synthesizing single stranded oligonucleotides on a DNA synthesizer and annealing with the complimentary strand by combining 4 μ g of both strands in a tube with total volume of 30 μ l of annealing buffer (5 mM NaCl, 10 mM Tris-HCl and 0.2 mM EDTA),
- 53 boiling the tubes for 5 min and slowly cooling to room temperature for 6 h,
- 54 Heating the tubes to 55 °C for 5 min and then cooling on ice for 10 min,
- 55 Quantitating 4 μ l aliquot of the annealed oligos at 260 λ and storing the remainder at -20 °C until radiolabeled,
- 56 Preparing probes by radiolabeling 200 ng of annealed oligonucleotide in 15 μ l of total volume containing 50 μ Ci of [γ -³²P]ATP (6,000 Ci/mmol), 20 Units of T4 polynucleotide kinase, and 1.5 μ l 10X T4 polynucleotide kinase buffer for 1 h at 37 °C,
- 57 Filling in the 5' over-hang ends with 5 Units of Klenow with 3.0 μ l of 10X Klenow buffer and 0.15 mM each of dATP, dCTP, dGTP, and dTTP for 40 min at 37 °C in a reaction volume of 30 μ l,

- 58 Increasing the volume to 1 ml with sterile TE with 200 mM NaCl, pH 8.0, and the labeled oligonucleotides were purified on a NACS Prepac column, to separate the unincorporated nucleotides,
- 59 Precipating the labeled, purified oligonucleotides overnight with 3 vol absolute ethanol at -20 °C,
- 60 Centrifuging at 13,000 rpm for 1 h and then vacuum drying,
- 61 Resuspending the labeled oligonucleotide probes in 100 µl of sterile 0.1X TE buffer and storing at -20 °C,
- 62 Electrophoretic mobility shift assay,
- 63 Incubating 5 µg of nuclear or cytoplasmic extract, for each reaction, with 0.2-0.3 ng of [γ - 32 P]ATP labeled oligonucleotide probe containing either NF- κ B sequence (5'-gatccGGGACTTTCCGCTGGGGACTTTCCG-3') or an AP-1 consensus sequence including the PMA responsive element indicated in bold (5'-gatcc**GTGACTCAGCGCG**-3'),
- 64 Adding 3 µg of poly(dI-dC):poly(dI-dC) as a non-specific competitor and incubating with the nuclear extracts for 10 min prior to the addition of the radiolabeled probe,
- 65 Adding antibodies against p65, p50, *c-Fos* or *c-Jun* to the respective binding reactions for supershift assays and incubating at room temperature for 1.5 h, prior to probing with [γ - 32 P]ATP labeled oligonucleotide for an additional 25 min at room temperature,
- 66 Separating the bound complexes on either a 5% ,for supershift assays, or 6% ,for analytical purposes, acrylamide/bis (30:1 ratio) native gel as required and running at 200v for 3.5 h with 0.25X TBE (0.02 M Tris-borate, 0.5 mM EDTA) as running buffer at room temperature,

67 Vacuum drying the gel with heat at 80 °C and exposing them to Kodak X-OMAT film for 3-12 hours,

68 Analyzing the bound and free DNA protein complexes.

ABSTRACT OF THE DISCLOSURE

A rapid isolation method permits the isolation of DNAs, RNAs and transcription factors simultaneously from a wide range of lymphoid and non-lymphoid cells, either from patients or in culture, without the loss of biological activity. A significant advantage of this method is that it entails minimal handling of samples from the patients with various disease states and pathogenic conditions such as AIDS, hepatitis, and other infectious diseases, which require substantial precautions during isolation of DNAs and proteins.

1/14




Fig. 1

2/14




Fig. 2

3/14




Fig. 3

4/14




Fig. 4 A

5/14

- 6 Centrifuging at 2,000 rpm for 5 min at 4 °C removing the PBS
processing the cell pellets following according to the protein

and DNA isolation steps comprising,



- 7 Preparing Buffer A: (cell lysis buffer), [20 mM Hepes, pH 7.9,
10 mM NaCl, 3 mM MgCl₂, 0.1% NP-40, 10% glycerol, 0.2
mM EDTA, 1 mM dithiothreitol (DTT), 0.4 mM
phenylmethylsulfonyl fluoride (PMSF), antipain (1 µg/ml),

leupeptin (1 µg/ml)],



- 8 Preparing Buffer B: (extraction buffer without salt), [20 mM
Hepes, pH 7.9, 0.2 mM EDTA, 20% glycerol, 1 mM DTT, 0.4
mM PMSF, antipain (1 µg/ml), leupeptin (1 µg/ml)],



- 9 Preparing Buffer C: (extraction buffer with salt), [20 mM
Hepes, pH 7.9, 400 mM NaCl, 0.2 mM EDTA, 20% glycerol, 1
mM DTT, 0.4 mM PMSF, antipain (1 µg/ml), leupeptin (1

µg/ml)],



Fig. 4 B

6/14

10 Preparing Buffer D: (cytoplasmic extraction clarification buffer), [20 mM Hepes, pH 7.9, 400 mM NaCl, 0.2 mM EDTA, 40% glycerol, 1 mM DTT, 0.4 mM PMSF, antipain (1 $\mu\text{g/ml}$), leupeptin (1 $\mu\text{g/ml}$)],



11 Performing Simultaneous isolation of protein and DNA comprising the steps of,



12 Resuspending the cell pellets in 100-125 μl (2 pellet vol) of Buffer A,



13 Maintaining the resuspended cell pellets on ice for 10-15 min with occasional tapping,



14 Pelleting the nuclei by centrifuging at 2,000 rpm for 5 min at 4°C,



15 Removing the cytoplasmic supernatant fraction to a second Eppendorf tube,



Fig. 4 C

09635037-080400
004080-22056960

7/14




Fig. 4 D

8/14

23 Quick freezing the remaining pellet containing nucleic acids

and other debris,



24 Storing at -86°C ,



25 Clarifying the cytoplasmic fraction by adding 1/3 vol of

Buffer D to this fraction for 30 min at 4°C to equilibrate the

cytoplasmic proteins with NaCl,



26 Centrifuging at 13,000 rpm for 15 min.,



27 Removing and quick freezing the supernatants and storing at -

86°C ,



28 Performing DNA extraction and analysis comprising the steps

of,



29 Thawing frozen cell pellets from on ice for 10 min,



30 Adding 100 μl of Buffer [0.1 % SDS, 10 mM Tris-HCl, pH 7.9,

10 mM EDTA, 10 mM NaCl] for 15 min,



Fig. 4 E

9/14




Fig. 4 F

10/14




Fig. 4 G

11/14




Fig. 4 H

12/14

56 Preparing probes by radiolabeling 200 ng of annealed oligonucleotide in 15 μ l of total volume containing 50 μ Ci of [γ - 32 P]ATP (6,000 Ci/mmol), 20 Units of T4 polynucleotide kinase, and 1.5 μ l 10X T4 polynucleotide kinase buffer for 1 h

at 37 $^{\circ}$ C,



57 Filling in the 5' over-hang ends with 5 Units of Klenow with 3.0 μ l of 10X Klenow buffer and 0.15 mM each of dATP, dCTP, dGTP, and dTTP for 40 min at 37 $^{\circ}$ C in a reaction

volume of 30 μ l.



58 Increasing the volume to 1 ml with sterile TE with 200 mM NaCl, pH 8.0, and the labeled oligonucleotides were purified on a NACS Prepac column, to separate the unincorporated

nucleotides,



59 Precipitating the labeled, purified oligonucleotides overnight

with 3 vol absolute ethanol at -20 $^{\circ}$ C,



Fig. 4 I

13/14

60 Centrifuging at 13,000 rpm for 1 h and then vacuum drying,



61 Resuspending the labeled oligonucleotide probes in 100 μ l of
sterile 0.1X TE buffer and storing at -20 $^{\circ}$ C,



62 Electrophoretic mobility shift assay,



63 Incubating 5 μ g of nuclear or cytoplasmic extract, for each
reaction, with 0.2-0.3 ng of [γ - 32 P]ATP labeled
oligonucleotide probe containing either NF- κ B sequence (5'-
gatccGGGACTTTCCGCTGGGGACTTTCCG-3') or an AP-1
consensus sequence including the PMA responsive element
indicated in bold (5'-gatcc**GTGACTC**AGCGCG-3'),



64 Adding 3 μ g of poly(dI-dC):poly(dI-dC) as a non-specific
competitor and incubating with the nuclear extracts for 10 min
prior to the addition of the radiolabeled probe,



Fig. 4 J

14/14

65 Adding antibodies against p65, p50, c-Fos or c-Jun to the
respective binding reactions for supershift assays and
incubating at room temperature for 1.5 h, prior to probing with
[γ -³²P]ATP labeled oligonucleotide for an additional 25 min at

room temperature,



66 Separating the bound complexes on either a 5% ,for supershift
assays, or 6% ,for analytical purposes, acrylamide/bis (30:1
ratio) native gel as required and running at 200v for 3.5 h with
0.25X TBE (0.02 M Tris-borate, 0.5 mM EDTA) as running

buffer at room temperature,



67 Vacuum drying the gel with heat at 80 °C and exposing them
to Kodak X-OMAT film for 3-12 hours,



68 Analyzing the bound and free DNA protein complexes.

Fig. 4 K

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)
Approved for use through 9/30/00. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | |
|---|-------------------------------|-----------------|
| DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63) <input checked="" type="checkbox"/> Declaration Submitted with Initial Filing OR <input type="checkbox"/> Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required) | Attorney Docket Number | |
| | First Named Inventor | RANJIT BANERJEE |
| | COMPLETE IF KNOWN | |
| | Application Number | / |
| | Filing Date | |
| | Group Art Unit | |
| | Examiner Name | |

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**METHODS FOR SIMULTANEOUS ISOLATION OF
BIOLOGICALLY ACTIVE TRANSCRIPTION FACTORS AND DNA**

the specification of which
☒ is attached hereto
OR
☐ was filed on (MM/DD/YYYY) [] as United States Application Number or PCT International Application Number [] and was amended on (MM/DD/YYYY) [] (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

| Prior Foreign Application Number(s) | Country | Foreign Filing Date (MM/DD/YYYY) | Priority Not Claimed | Certified Copy Attached? | |
|-------------------------------------|---------|----------------------------------|--------------------------|--------------------------|--------------------------|
| | | | | YES | NO |
| | | | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| | | | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| | | | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| | | | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

| Application Number(s) | Filing Date (MM/DD/YYYY) | <input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto. |
|-----------------------|--------------------------|--|
| 60/147 270 | 08/05/1999 | |

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)
Approved for use through 9/30/00. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

| U.S. Parent Application or PCT Parent Number | Parent Filing Date (MM/DD/YYYY) | Parent Patent Number (if applicable) |
|--|---------------------------------|--------------------------------------|
| | | |

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☐ Customer Number

OR

☒ Registered practitioner(s) name/registration number listed below

Place Customer
Number Bar Code
Label here

| Name | Registration Number | Name | Registration Number |
|----------------------|---------------------|------|---------------------|
| ARTHUR I. DEGENHOLTZ | 22914 | | |

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☐ Customer Number or Bar Code Label OR ☒ Correspondence address below

| | | | | | |
|---------|----------------------|-----------|--------------|-----|--------------|
| Name | ARTHUR I. DEGENHOLTZ | | | | |
| Address | 32 VANDELINDA AVE. | | | | |
| Address | | | | | |
| City | TEANECK | State | NJ | ZIP | 07666 |
| Country | US | Telephone | 201 692 1292 | Fax | 201 692 9764 |

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

| | | | | | |
|--|-----------------|---|----|---------|--------|
| Name of Sole or First Inventor: | | <input type="checkbox"/> A petition has been filed for this unsigned inventor | | | |
| Given Name (first and middle (if any)) | | Family Name or Surname | | | |
| RAJIT | | BAWERTJEE | | | |
| Inventor's Signature | Rajit Bawertjee | | | Date | 8/1/00 |
| Residence: City | TEANECK | State | NJ | Country | US |
| Post Office Address | 655 MILDRED ST. | | | | |
| Post Office Address | 655 MILDRED ST | | | | |
| City | TEANECK | State | NJ | ZIP | 07666 |
| | | | | Country | US |

☐ Additional inventors are being named on the supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto